�山ǿ�� News - amyotrophic lateral sclerosis

Multiple ALS projects at The Neuro awarded funding

webfull — Mon, 15 Feb 2021 15:29:35 +0000

Program brings together multidisciplinary teams with expertise in various areas of neurodegenerative disease

Researchers at The Neuro (Montreal Neurological Institute-Hospital) make up a large part of eight projects funded by ALS Canada and the Brain Canada Foundation as part of their 2020 Discovery Grant Program, which brings together multidisciplinary research teams with expertise in various areas of ALS and neurodegenerative diseases to investigate critical areas of disease processes and clinical care.

Published: 15 February 2021

Improving research with more effective antibodies

webfull — Tue, 15 Oct 2019 16:55:16 +0000

Scientists demonstrate flaws in protein detection tools, and outline a solution

A new study points to the need for better antibody validation, and outlines a process that other labs can use to make sure the antibodies they work with function properly.

Antibodies are used in laboratories and clinics to study proteins, which are the biomolecules that translate information from an organism’s genes into the structure, function, and regulation of its tissues and organs. Genetic mutations can cause protein imbalances or malfunctions, leading to human disease.

Published: 15 October 2019

The MNI forms promising Open Science partnership with Takeda

webfull — Mon, 04 Dec 2017 19:37:18 +0000

Industry and academia team up for the benefit of people suffering from ALS

A unique industry-academia partnership will increase the rate at which promising drug compounds can be tested as potential treatments for amyotrophic lateral sclerosis (ALS), a disease with no known cure that affects 200,000 people worldwide.

The partnership between The Montreal Neurological Institute and Hospital (MNI) and Takeda Pharmaceutical Company Limited (Takeda) will allow compounds developed by Takeda scientists to be tested on cell lines produced at the MNI.

Published: 4 December 2017

The Neuro to create world’s first ALS Phase 1 clinical trial unit

webfull — Mon, 03 Jul 2017 19:07:23 +0000

The Tenaquip Foundation donation will allow for faster drug development, better care for ALS patients

A generous donation by The Tenaquip Foundation will improve the quality of care available to ALS patients at The Neuro, and increase the rate at which researchers can evaluate new ALS drugs.

Published: 3 July 2017

ALS – Fostering awareness of a devastating disease

webfull — Fri, 02 Jun 2017 14:59:33 +0000

ALS takes away the patient’s motor functions one at a time, and the progress of finding effective drugs to counter its insidious effects has been slow. June is ALS Month, a good time to update the public on the latest developments in ALS research taking place at The Neuro.

The Montreal Neurological Institute and Hospital (The Neuro) is recognized as a leading Canadian centre for research into amyotrophic lateral sclerosis (ALS) as well as for its care of ALS patients.

Published: 2 June 2017

ALS Awareness Month – June 2016

webfull — Mon, 13 Jun 2016 13:51:58 +0000

The Neuro is recognized as a major Canadian center for ALS research and patient care. During June, designated ALS Month, The Neuro redoubles its efforts to inform the public and the media about amyotrophic lateral sclerosis (ALS), and urges all to help support ALS research.

Published: 13 June 2016

ALS Awareness Month – June

webfull — Tue, 02 Jun 2015 14:36:57 +0000

As a major Canadian centre for amyotrophic lateral sclerosis (ALS) research and treatment, the Montreal Neurological Institute and Hospital - The Neuro, invites the public and the media to learn more about the disease and current research and treatments, to donate money for ALS research and to wear the national emblem of ALS in Canada, the blue cornflower, during ALS Awareness Month in June.

Published: 2 June 2015